Candidate chromosome 1 disease susceptibility genes for Sjogren's syndrome xerostomia are narrowed by novel NOD. B10 congenic mice

Clinical Immunology

Volumn 153, Issue 1, 2014, Pages 79-90

  Mongini, Patricia K A ^a   Kramer, Jill M ^a,d   Ishikawa, Tomo o ^b,e   Herschman, Harvey ^b   Esposito, Donna ^c  

^a Northwell Health   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c CHARLES RIVER LABORATORIES   (United States)

^d School of Dental Medicine at SUNY   (United States)

^e TransGenic Inc Kobe Research Center   (Japan)

Author keywords

B lymphocytes; Cyclooxygenase 2; Genetic susceptibility; NOD mice; Sjogren's syndrome

Indexed keywords

B LYMPHOCYTES; CYCLOOXYGENASE-2; GENETIC SUSCEPTIBILITY; NOD MICE; SJOGREN'S SYNDROME;

ANIMALS; CHROMOSOME MAPPING; CHROMOSOMES, MAMMALIAN; CYCLOOXYGENASE 2; DISEASE MODELS, ANIMAL; FEMALE; GENE EXPRESSION; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; MICE; MICE, CONGENIC; MICE, INBRED NOD; OPEN READING FRAMES; RECOMBINATION, GENETIC; SALIVARY GLANDS; SIALADENITIS; SJOGREN'S SYNDROME; XEROSTOMIA;

EID: 84899140440     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2014.03.012     Document Type: Article

References (65)

1. Voulgarelis M., Tzioufas A.G. Pathogenetic mechanisms in the initiation and perpetuation of Sjogren's syndrome. Nat. Rev. Rheumatol. 2010, 6:529-537.
2. Ekstrom Smedby K., Vajdic C.M., Falster M., Engels E.A., Martinez-Maza O., Turner J., et al. Autoimmune disorders and risk of non-Hodgkin lymphoma subtypes: a pooled analysis within the InterLymph Consortium. Blood 2008, 111:4029-4038.
3. Mariette X., Roux S., Zhang J., Bengoufa D., Lavie F., Zhou T., et al. The level of BLyS (BAFF) correlates with the titre of autoantibodies in human Sjogren's syndrome. Ann. Rheum. Dis. 2003, 62:168-171.
4. Nguyen C.Q., Gao J.H., Kim H., Saban D.R., Cornelius J.G., Peck A.B. IL-4-STAT6 signal transduction-dependent induction of the clinical phase of Sjogren's syndrome-like disease of the nonobese diabetic mouse. J. Immunol. 2007, 179:382-390.
5. Robinson C.P., Brayer J., Yamachika S., Esch T.R., Peck A.B., Stewart C.A., et al. Transfer of human serum IgG to nonobese diabetic Igmu null mice reveals a role for autoantibodies in the loss of secretory function of exocrine tissues in Sjogren's syndrome. Proc. Natl. Acad. Sci. U. S. A. 1998, 95:7538-7543.
6. St Clair E.W., Levesque M.C., Prak E.T., Vivino F.B., Alappatt C.J., Spychala M.E., et al. Rituximab therapy for primary Sjogren's syndrome: an open-label clinical trial and mechanistic analysis. Arthritis Rheum. 2013, 65:1097-1106.
7. Salomonsson S., Jonsson M.V., Skarstein K., Brokstad K.A., Hjelmstrom P., Wahren-Herlenius M., et al. Cellular basis of ectopic germinal center formation and autoantibody production in the target organ of patients with Sjogren's syndrome. Arthritis Rheum. 2003, 48:3187-3201.
8. Huang Y.F., Cheng Q., Jiang C.M., An S., Xiao L., Gou Y.C., et al. The immune factors involved in the pathogenesis, diagnosis, and treatment of Sjogren's syndrome. Clin. Dev. Immunol. 2013, 160491.
9. Gao J., Killedar S., Cornelius J.G., Nguyen C., Cha S., Peck A.B. Sjogren's syndrome in the NOD mouse model is an interleukin-4 time-dependent, antibody isotype-specific autoimmune disease. J. Autoimmun. 2006, 26:90-103.
10. Cha S., Singson E., Cornelius J., Yagna J.P., Knot H.J., Peck A.B. Muscarinic acetylcholine type-3 receptor desensitization due to chronic exposure to Sjogren's syndrome-associated autoantibodies. J. Rheumatol. 2006, 33:296-306.
11. Tsuboi H., Matsumoto I., Wakamatsu E., Nakamura Y., Iizuka M., Hayashi T., et al. New epitopes and function of anti-M3 muscarinic acetylcholine receptor antibodies in patients with Sjogren's syndrome. Clin. Exp. Immunol. 2010, 162:53-61.
12. Dawson L.J., Stanbury J., Venn N., Hasdimir B., Rogers S.N., Smith P.M. Antimuscarinic antibodies in primary Sjogren's syndrome reversibly inhibit the mechanism of fluid secretion by human submandibular salivary acinar cells. Arthritis Rheum. 2006, 54:1165-1173.
13. Nguyen C.Q., Hu M.H., Li Y., Stewart C., Peck A.B. Salivary gland tissue expression of interleukin-23 and interleukin-17 in Sjogren's syndrome: findings in humans and mice. Arthritis Rheum. 2008, 58:734-743.
14. Park H., Li Z., Yang X.O., Chang S.H., Nurieva R., Wang Y.H., et al. A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat. Immunol. 2005, 6:1133-1141.
15. Mitsdoerffer M., Lee Y., Jager A., Kim H.J., Korn T., Kolls J.K., et al. Proinflammatory T helper type 17 cells are effective B-cell helpers. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:14292-14297.
16. Zhang M.A., Rego D., Moshkova M., Kebir H., Chruscinski A., Nguyen H., et al. Peroxisome proliferator-activated receptor (PPAR)alpha and gamma regulate IFNgamma and IL-17A production by human T cells in a sex-specific way. Proc. Natl. Acad. Sci. U. S. A. 2012, 109:9505-9510.
17. Bettelli E., Carrier Y., Gao W., Korn T., Strom T.B., Oukka M., et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 2006, 441:235-238.
18. Khayrullina T., Yen J.H., Jing H., Ganea D. In vitro differentiation of dendritic cells in the presence of prostaglandin E2 alters the IL-12/IL-23 balance and promotes differentiation of Th17 cells. J. Immunol. 2008, 181:721-735.
19. Yao C., Sakata D., Esaki Y., Li Y., Matsuoka T., Kuroiwa K., et al. Prostaglandin E2-EP4 signaling promotes immune inflammation through Th1 cell differentiation and Th17 cell expansion. Nat. Med. 2009, 15:633-640.
20. Boniface K., Bak-Jensen K.S., Li Y., Blumenschein W.M., McGeachy M.J., McClanahan T.K., et al. Prostaglandin E2 regulates Th17 cell differentiation and function through cyclic AMP and EP2/EP4 receptor signaling. J. Exp. Med. 2009, 206:535-548.
21. Lessard C.J., Li H., Adrianto I., Ice J.A., Rasmussen A., Grundahl K.M., et al. Variants at multiple loci implicated in both innate and adaptive immune responses are associated with Sjogren's syndrome. Nat. Genet. 2013, 45:1284-1292.
22. Cha S., Nagashima H., Brown V.B., Peck A.B., Humphreys-Beher M.G. Two NOD Idd-associated intervals contribute synergistically to the development of autoimmune exocrinopathy (Sjogren's syndrome) on a healthy murine background. Arthritis Rheum. 2002, 46:1390-1398.
23. Nguyen C.Q., Cornelius J.G., Cooper L., Neff J., Tao J., Lee B.H., et al. Identification of possible candidate genes regulating Sjogren's syndrome-associated autoimmunity: a potential role for TNFSF4 in autoimmune exocrinopathy. Arthritis Res. Ther. 2008, 10:R137.
24. Nguyen C., Singson E., Kim J.Y., Cornelius J.G., Attia R., Doyle M.E., et al. Sjogren's syndrome-like disease of C57BL/6.NOD-Aec1 Aec2 mice: gender differences in keratoconjunctivitis sicca defined by a cross-over in the chromosome 3 Aec1 locus. Scand. J. Immunol. 2006, 64:295-307.
25. Ryan E.P., Malboeuf C.M., Bernard M., Rose R.C., Phipps R.P. Cyclooxygenase-2 inhibition attenuates antibody responses against human papillomavirus-like particles. J. Immunol. 2006, 177:7811-7819.
26. Roper R.L., Phipps R.P. Prostaglandin E2 and cAMP inhibit B lymphocyte activation and simultaneously promote IgE and IgG1 synthesis. J. Immunol. 1992, 149:2984-2991.
27. Mongini P.K., Inman J.K., Han H., Fattah R.J., Abramson S.B., Attur M. APRIL and BAFF promote increased viability of replicating human B2 cells via mechanism involving cyclooxygenase 2. J. Immunol. 2006, 176:6736-6751.
28. Lee H., Trott J.S., Haque S., McCormick S., Chiorazzi N., Mongini P.K. A cyclooxygenase-2/prostaglandin E2 pathway augments activation-induced cytosine deaminase expression within replicating human B cells. J. Immunol. 2010, 185:5300-5314.
29. Ishikawa T.O., Herschman H.R. Conditional knockout mouse for tissue-specific disruption of the cyclooxygenase-2 (Cox-2) gene. Genesis 2006, 44:143-149.
30. Narasimha A.J., Watanabe J., Ishikawa T.O., Priceman S.J., Wu L., Herschman H.R., et al. Absence of myeloid COX-2 attenuates acute inflammation but does not influence development of atherosclerosis in apolipoprotein E null mice. Arterioscler. Thromb. Vasc. Biol. 2010, 30:260-268.
31. Wong G.T. Speed congenics: applications for transgenic and knock-out mouse strains. Neuropeptides 2002, 36:230-236.
32. Eppig J.T., Blake J.A., Bult C.J., Kadin J.A., Richardson J.E. The Mouse Genome Database (MGD): comprehensive resource for genetics and genomics of the laboratory mouse. Nucleic Acids Res. 2012, 40:D881-D886.
33. Robinson C.P., Yamachika S., Bounous D.I., Brayer J., Jonsson R., Holmdahl R., et al. A novel NOD-derived murine model of primary Sjogren's syndrome. Arthritis Rheum. 1998, 41:150-156.
34. Deshmukh U.S., Ohyama Y., Bagavant H., Guo X., Gaskin F., Fu S.M. Inflammatory stimuli accelerate Sjogren's syndrome-like disease in (NZB×NZW)F1 mice. Arthritis Rheum. 2008, 58:1318-1323.
35. Vitali C., Bombardieri S., Jonsson R., Moutsopoulos H.M., Alexander E.L., Carsons S.E., et al. Classification criteria for Sjogren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann. Rheum. Dis. 2002, 61:554-558.
36. Nguyen C.Q., Peck A.B. Unraveling the pathophysiology of Sjogren syndrome-associated dry eye disease. Ocul. Surf. 2009, 7:11-27.
37. Jonsson M.V., Delaleu N., Brokstad K.A., Berggreen E., Skarstein K. Impaired salivary gland function in NOD mice: association with changes in cytokine profile but not with histopathologic changes in the salivary gland. Arthritis Rheum. 2006, 54:2300-2305.
38. Hoppeler-Lebel A., Celati C., Bellett G., Mogensen M.M., Klein-Hitpass L., Bornens M., et al. Centrosomal CAP350 protein stabilises microtubules associated with the Golgi complex. J. Cell Sci. 2007, 120:3299-3308.
39. Patel H., Truant R., Rachubinski R.A., Capone J.P. Activity and subcellular compartmentalization of peroxisome proliferator-activated receptor alpha are altered by the centrosome-associated protein CAP350. J. Cell Sci. 2005, 118:175-186.
40. Aleshin S., Strokin M., Sergeeva M., Reiser G. Peroxisome proliferator-activated receptor (PPAR)beta/delta, a possible nexus of PPARalpha- and PPARgamma-dependent molecular pathways in neurodegenerative diseases: Review and novel hypotheses. Neurochem. Int. 2013, 63:322-330.
41. Choi J.M., Bothwell A.L. The nuclear receptor PPARs as important regulators of T-cell functions and autoimmune diseases. Mol. Cells 2012, 33:217-222.
42. Dunn S.E., Ousman S.S., Sobel R.A., Zuniga L., Baranzini S.E., Youssef S., et al. Peroxisome proliferator-activated receptor (PPAR)alpha expression in T cells mediates gender differences in development of T cell-mediated autoimmunity. J. Exp. Med. 2007, 204:321-330.
43. Dron M., Meritet J.F., Dandoy-Dron F., Meyniel J.P., Maury C., Tovey M.G. Molecular cloning of ADIR, a novel interferon responsive gene encoding a protein related to the torsins. Genomics 2002, 79:315-325.
44. Nordmark G., Alm G.V., Ronnblom L. Mechanisms of disease: primary Sjogren's syndrome and the type I interferon system. Nat. Clin. Pract. Rheumatol. 2006, 2:262-269.
45. Nguyen C.Q., Peck A.B. The Interferon-Signature of Sjogren's Syndrome: How Unique Biomarkers Can Identify Underlying Inflammatory and Immunopathological Mechanisms of Specific Diseases. Front. Immunol. 2013, 4:142.
46. Gonzalez-Begne M., Lu B., Han X., Hagen F.K., Hand A.R., Melvin J.E., et al. Proteomic analysis of human parotid gland exosomes by multidimensional protein identification technology (MudPIT). J. Proteome Res. 2009, 8:1304-1314.
47. van Bergen C.A., Kester M.G., Jedema I., Heemskerk M.H., van Luxemburg-Heijs S.A., Kloosterboer F.M., et al. Multiple myeloma-reactive T cells recognize an activation-induced minor histocompatibility antigen encoded by the ATP-dependent interferon-responsive (ADIR) gene. Blood 2007, 109:4089-4096.
48. Glimcher L.H., Longo D.L., Green I., Schwartz R.H. Murine syngeneic mixed lymphocyte response. I. Target antigens are self Ia molecules. J. Exp. Med. 1981, 154:1652-1670.
49. Gu J.J., Ryu J.R., Pendergast A.M. Abl tyrosine kinases in T-cell signaling. Immunol. Rev. 2009, 228:170-183.
50. Liberatore R.A., Goff S.P. c-Abl-deficient mice exhibit reduced numbers of peritoneal B-1 cells and defects in BCR-induced B cell activation. Int. Immunol. 2009, 21:403-414.
51. Zhao C., Brown R.S., Chase A.R., Eisele M.R., Schlieker C. Regulation of Torsin ATPases by LAP1 and LULL1. Proc. Natl. Acad. Sci. U. S. A. 2013, 110:E1545-E1554.
52. Goodchild R.E., Dauer W.T. The AAA+protein torsinA interacts with a conserved domain present in LAP1 and a novel ER protein. J. Cell Biol. 2005, 168:855-862.
53. Simon D.N., Wilson K.L. The nucleoskeleton as a genome-associated dynamic 'network of networks'. Nat. Rev. Mol. Cell Biol. 2011, 12:695-708.
54. Katchman B.A., Ocal I.T., Cunliffe H.E., Chang Y.H., Hostetter G., Watanabe A., et al. Expression of quiescin sulfhydryl oxidase 1 is associated with a highly invasive phenotype and correlates with a poor prognosis in Luminal B breast cancer. Breast Cancer Res. 2013, 15:R28.
55. Lu Z., Yuan Z., Miyoshi T., Wang Q., Su Z., Chang C.C., et al. Identification of Soat1 as a quantitative trait locus gene on mouse chromosome 1 contributing to hyperlipidemia. PLoS One 2011, 6:e25344.
56. Nguyen C.Q., Sharma A., She J.X., McIndoe R.A., Peck A.B. Differential gene expressions in the lacrimal gland during development and onset of keratoconjunctivitis sicca in Sjogren's syndrome (SJS)-like disease of the C57BL/6.NOD-Aec1Aec2 mouse. Exp. Eye Res. 2009, 88:398-409.
57. McLaughlin S.K., Olsen S.N., Dake B., De Raedt T., Lim E., Bronson R.T., et al. The RasGAP gene, RASAL2, is a tumor and metastasis suppressor. Cancer Cell 2013, 24:365-378.
58. Soupene E., Serikov V., Kuypers F.A. Characterization of an acyl-coenzyme A binding protein predominantly expressed in human primitive progenitor cells. J. Lipid Res. 2008, 49:1103-1112.
59. Huang S.K., Scruggs A.M., Donaghy J., McEachin R.C., Fisher A.S., Richardson B.C., et al. Prostaglandin E(2) increases fibroblast gene-specific and global DNA methylation via increased DNA methyltransferase expression. FASEB J. 2012, 26:3703-3714.
60. Xia D., Wang D., Kim S.H., Katoh H., DuBois R.N. Prostaglandin E2 promotes intestinal tumor growth via DNA methylation. Nat. Med. 2012, 18:224-226.
61. Ishikawa T.O., Jain N., Herschman H.R. Feedback regulation of cyclooxygenase-2 transcription ex vivo and in vivo. Biochem. Biophys. Res. Commun. 2009, 378:534-538.
62. Steinert D., Kuper C., Bartels H., Beck F.X., Neuhofer W. PGE2 potentiates tonicity-induced COX-2 expression in renal medullary cells in a positive feedback loop involving EP2-cAMP-PKA signaling. Am. J. Physiol. Cell Physiol. 2009, 296:C75-C87.
63. Toyota M., Shen L., Ohe-Toyota M., Hamilton S.R., Sinicrope F.A., Issa J.P. Aberrant methylation of the cyclooxygenase 2 CpG island in colorectal tumors. Cancer Res. 2000, 60:4044-4048.
64. Eisen M.B., Spellman P.T., Brown P.O., Botstein D. Cluster analysis and display of genome-wide expression patterns. Proc. Natl. Acad. Sci. U. S. A. 1998, 95:14863-14868.
65. Dottorini T., Palladino P., Senin N., Persampieri T., Spaccapelo R., Crisanti A. CluGene: A Bioinformatics Framework for the Identification of Co-Localized, Co-Expressed and Co-Regulated Genes Aimed at the Investigation of Transcriptional Regulatory Networks from High-Throughput Expression Data. PLoS One 2013, 8:e66196.